Skip to main content
Current Neuropharmacology logoLink to Current Neuropharmacology
. 2016 Aug;14(6):619–626. doi: 10.2174/1570159X14666160119094959

Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia

Anil Gulati 1,*
PMCID: PMC4981738  PMID: 26786146

Abstract

Background: Neurogenesis is most active during pre-natal development, however, it persists throughout the human lifespan. The putative role of mitochondria in neurogenesis and angiogenesis is gaining importance. Since, ETB receptor mediated neurogenesis and angiogenesis has been identified, the role of these receptors with relevance to mitochondrial functions is of interest.

Methods: In addition to work from our laboratory, we undertook an extensive search of bibliographic databases for peer-reviewed research literature. Specific technical terms such as endothelin, mitochondria and neurogenesis were used to seek out and critically evaluate literature that was relevant.

Results: The ET family consists of three isopeptides (ET-1, ET-2 and ET-3) that produce biological actions by acting on two types of receptors (ETA and ETB). In the central nervous system (CNS) ETA receptors are potent constrictors of the cerebral vasculature and appear to contribute in the causation of cerebral ischemia. ETA receptor antagonists have been found to be effective in animal model of cerebral ischemia; however, clinical studies have shown no efficacy. Mitochondrial functions are critically important for several neural development processes such as neurogenesis, axonal and dendritic growth, and synaptic formation. ET appears to impair mitochondrial functions through activation of ETA receptors. On the other hand, blocking ETB receptors has been shown to trigger apoptotic processes by activating intrinsic mitochondrial pathway. Mitochondria are important for their role in molecular regulation of neurogenesis and angiogenesis. Stimulation of ETB receptors in the adult ischemic brain has been found to promote angiogenesis and neurogenesis mediated through vascular endothelial growth factor and nerve growth factor. It will be interesting to investigate the effect of ETB receptor stimulation on mitochondrial functions in the CNS following cerebral ischemia.

Conclusion: The findings of this review implicate brain ETB receptors in angiogenesis and neurogenesis following cerebral ischemia, it is possible that the positive effect of stimulating ETB receptors in cerebral ischemia may be mediated through mitochondrial functions.

Keywords: Cerebral ischemia, endothelin, ETB receptor, mitochondria, neurogenesis, nerve growth factor, vascular endothelial growth factor

1. INTRODUCTION

1.1. Endothelin

Endothelin (ET) was first isolated from porcine aortic endothelial cells and characterized as the most potent vasoconstrictor substance in 1988 [1]. It consists of 21 amino acid residues with two disulfide intramolecular bonds [1]. It was also found that there are 3 isopeptides of ET in the mammalian tissues: ET-1, ET-2 and ET-3 [1, 2]. All three endogenous isopeptides have since been implicated in a number of physiological and pathological roles including regulation of blood flow and pressure, apoptosis and immune modulation.

The biological responses of ET-1 are mediated through activation of two distinct G-protein-coupled receptors (GPCRs): ETA and ETB (Fig. 1). These receptors consist of seven hydrophobic transmembrane domains, with an intracytoplasmic C terminus and an extracellular N terminus [3]. Variations in the C terminus account for differences in the binding affinities of the three isopeptides to each receptor. While all three ETs have equal affinity for the ETB receptor, ET-3 has a lower affinity for the ETA receptor compared to either ET-1 or ET-2 [4].

Fig. (1).

Fig. (1)

There are two types of ET receptors: ETA and ETB. ETA receptors are found on the vascular smooth muscle and are vasoconstrictor. ETB receptors are identified as ETB1 and ETB2 based upon pharmacological response to RES701. RES701 was found to block ETB1 (located on vascular endothelial cells and function as dilator) but not ETB2 (located on vascular smooth muscle cells and function as constrictor).

In the cardiovascular system, vascular smooth muscle cells have ETA receptors which produce vasoconstriction via a biphasic increase in intracellular [Ca2+] [5]. ETB receptors, on the other hand, are primarily located on vascular endothelial cells, where they are coupled to the activation of nitric oxide synthase (NOS) via calcium-calmodulin and protein tyrosine kinase-dependent mechanisms. This coupling causes a release of nitric oxide (NO) which in turn leads to vasodilatation [6]. Thus, ETA and ETB receptors have opposing roles in the vascular system (Fig. 1). In a rat, vascular smooth muscle cells also have ETB receptors, where along with ETA receptors, they mediate vasoconstriction [7]. ETB receptors are also located in the kidney, lung and the brain [8].

Remarkably, ET-1 is produced in significant amounts by the prostate and metastatic cancers. It is also made in high concentrations by the central nervous system (CNS). Neurons, astrocytes and glial cells of the CNS produce significant amount of ET-1 [8]. The wide spread distribution of ET-1 and its receptors in the brain suggests that, besides having vascular functions, ET-1 may also be involved in the regulation of CNS [9].

1.2. Involvement of Endothelin in the CNS

Studies have shown that ET is involved in the regulation of the sympathetic nervous system [10, 11]. Sympathetic nervous system mediated responses of clonidine have been demonstrated to be blocked by ET antagonists [10] and those of ET-1 by propranolol [11, 12]. Under normal physiological conditions, these centrally located receptors are important regulators of cerebral blood flow as well as developmental neuronal migration, proliferation and apoptosis [13, 14].

It is well established that ETB receptors are a necessary component of the developing nervous system. ETB receptors act as regulators in differentiation, proliferation and migration of neural cells during pre- and post-natal development, assisting the formation of melanocytes, neurons and glia of the enteric nervous system as well as the CNS [15, 16]. The presence of ETB receptors in the subependymal zone, an adult neurogenic niche, of adult rats has introduced the possibility that these receptors may not only regulate the developing CNS, but may play a role in remodeling the adult brain as well [17]. Intracerebroventricular administration of an ETB receptor agonist was found to increase brain-derived and glial-derived neurotrophic factors, and neurotrophin-3 in the brains of normal adult rats [18, 19].

1.3. Endothelin and Mitochondrial Functions

ET has been shown to produce some of its actions by modulating mitochondrial functions. ET-1 induced positive inotropic effect has been found to be associated with a surge in reactive oxygen species production, and ET-1 induced increases in superoxide anion was inhibited by NADPH oxidase blocker apocynin and by mitochondrial ATP-sensitive K+ channel blocker, glibenclamide [20]. An inhibitor of mitochondrial respiratory chain complex I, rotenone, significantly increased the expression of prepro ET-1 gene in the cardiomyocytes [21] indicating that ET-1 may produce impairment of mitochondrial functions leading to myocardial dysfunction in the failing heart. It has been demonstrated that the beneficial effect of ETA receptor antagonist, LU135252 in congestive heart failure is mediated through improvement in mitochondrial functions [22]. Acrolein induced mitochondrial generation of reactive oxygen species in the pulmonary artery endothelial cells along with an increase in ET-1 which were both blocked by rotenone indicating involvement of ET in mitochondrial functions [23]. Both ETA and ETB receptors are expressed in the glioblastoma cell lines and it has been found that ETB receptors mediate proliferation of different types of cancer cells [24, 25]. Furthermore, ETB receptor antagonists, BQ788 and A192621, attenuated the viability and proliferation of glioma cell lines as determined by incorporation of BrdU and cell cycle analysis. BQ788 and A192621 were found to trigger apoptotic processes by activating the intrinsic mitochondrial pathway [25] indicating involvement of ETB receptors in mitochondrial functions of glioma cell lines.

1.4. Neurogenesis

The process of neurogenesis is most active during pre-natal development. However, it persists throughout the human lifespan. Neurogenesis occurs predominantly in the subventricular zone (SVZ), lining the wall of the lateral ventricles, subgranular zone (SGZ) of the hippocampal dentate gyrus [26] and spinal cord [27] of the adult CNS. Many pharmacological agents such as insulin-like growth factor [28], vascular endothelial growth factor (VEGF) [29] and antidepressants [30], have been identified to modulate neurogenesis and can provide new therapeutic strategies for several CNS disorders such as stroke, traumatic brain injury, depression, Alzheimer’s disease and others. The present review will mainly focus on the neurogenesis in the adult brain and its implications in cerebral ischemia.

There are approximately 100 billion neurons in a mature human brain [31]. Each neuron can make connections with more than 1000 other neurons, and an adult brain can have approximately 60 trillion neuronal connections. Cells of other organs such as the skin and the immune system continuously divide and self-renew; however, a neuron in the adult brain, once formed from the parent stem cell, is not likely to undergo division [32]. It has long been the belief that plasticity of the nervous system involves modulating the connections between existing neurons. However, evidence shows that new neurons are being formed in the adult brain also [33, 34].

Neuronal production in human starts in the embryonic period around day 42 and occurs until mid-gestation. At 
first neural progenitor cells, which are mitotic, are formed 
in a symmetrical fashion till 42 embryonic days. After that, the mode of cell division shifts from symmetrical to asymmetrical. During asymmetrical division, one neuron and one neural progenitor are produced [35]. The newly formed progenitor neurons remain in the proliferative zone while the neurons migrate to the neocortex. The cortical neurogenesis is completed in about 108 embryonic days [36]. A naturally occurring process that is essential in the establishment of complex networks of the developing brain involves a loss of about 50% of the neurons. This non-pathological process of neuronal cell death occurs prenatally. Similarly, elimination of about 50% of exuberant connections between neurons occurs postnatally [31, 36]. Neurogenesis mostly occurs in the ventricular zone and newly formed neurons migrate radially out to the developing neocortex. It has been demonstrated that ETB receptors in the brain are over expressed at the time of birth and their expression decreases with age and maturity of the brain [37]. It appears that ETB receptors are important in the development of the brain and once the brain is developed, the need for ETB receptors decreases and therefore the expression of these receptors decreases. ETB receptors have been shown to increase the expression of various growth factors, such as VEGF and nerve growth factor (NGF), and have been implicated in playing an important role in the development of vascular and neuronal components of the CNS [38-40].

1.5. Mitochondria and Neurogenesis

The neuronal cells are highly dependent upon mitochondria for energy production. Mitophagy is the process by which undesired or damaged mitochondria are removed by autophagy and in this manner healthy functioning mitochondria are maintained. Mitochondria have a short life-span of 10 to 25 days compared to the life of neurons, mitophagy induced turnaround of mitochondria is the key to survival of neurons [41]. Impairment of mitophagy has been implicated in diseases such as Alzheimer’s disease [42-44], Parkinson’s disease [45] and in ischemic insults of the brain [46]. Mitophagy can be dependent or independent of parkin and prevents mitochondria from fusing with healthy ones and releasing pro-apoptotic proteins [42].

Physiological functioning of mitochondria is important for adult neurogenesis, a critical feature required to repair damaged neuronal tissue by cerebral ischemia. Neurogenesis requires adequate amount of ATP supply to facilitate cytoskeletal rearrangement, neuronal sprouting and organelle transport. Being a primary source of cellular ATP, healthy mitochondrial function is an important prerequisite to carryout neurogenesis effectively [47]. An enhanced mitochondrial mass appears to be the hallmark of adult neuronal differentiation, which indicates the importance of mitochondria in adult neurogenesis [48]. Increased ATP production is likely to be utilized for cytoskeletal rearrangement, mitochondrial dynamics and membrane turnover involved in neurite outgrowth. Some of the key mitochondrial proteins and transcription factors have been found to be elevated to high levels during neuronal differentiation. Increased expression of uncoupling protein (UCP4) and NeuroD6 mediated kinensin protein expression were observed at various stages of neurite outgrowth [49]. Mitochondria have been identified to be important for axonal growth cone formation, neural polarization and dendrite plasticization aspects of neurite outgrowth [50].

In addition to adult neurogenesis, mitochondria are also important for their role in molecular regulation of angiogenesis and vasculogenesis as evident from the experimental findings in cardiac tissue and cultured endothelial cells. Mitochondria have been found to directly influence hypoxia inducible factor (HIF-1α) signaling by release of reactive oxygen species and α-ketoglutarate, a cofactor for prolyl hydroxylation and destruction of HIF components [51]. Mitochondria thus link the metabolic derangements to the process of vascularization in both physiology and pathology. Mitofusins, functional proteins responsible for fusion of mitochondria have also been found to modulate the VEGF mediated Akt-eNOS signaling in endothelial cells [52].

The putative role of mitochondria in the neurogenesis and vasculogenesis emphasizes the importance of maintaining a healthy mitochondrial network in the context of cerebral ischemia. Various lines of evidence clearly indicate mitochondrial functional impairment in the ischemic nervous tissue and hence therapeutic alleviation of mitochondrial function can be an important target to treat cerebral ischemia [53]. The relation between ET receptor activation and mitochondrial function has been understudied in the case of nervous tissue. Although several reports of ET induced impairment of mitochondrial function in the cardiomyocytes exist, most of the effects mediated through ETA receptor activation. The role of ETB receptors should be studied in a neuronal ischemia model with relevance to mitochondrial function. Since, ETB mediated neurogenesis and vasculo-
genesis has been identified to play significant role in cerebral ischemia, a molecular assessment of downstream consequences of ETB activation on mitochondrial function could lead to better understanding of pathophysiology of stroke and help us to devise better therapeutic strategies.

1.6. Type of ET Receptors Involved in Neurogenesis

The release of neurotrophic and angiogenic factors, such as VEGF increases significantly via stimulation of ETB receptors on the astrocytes [54]. Both ETA and ETB receptors exist in the brain and play an important role. ETA receptor selective antagonists, BQ123 and BMS182874, were found to prevent amyloid beta (Aβ)-induced cognitive deficits. However, a nonspecific ETA and ETB receptor antagonist, TAK044, did not produce any improvement in memory deficit. This lack of improvement with the non-specific ETA and ETB antagonist indicated specific involvement of ETB receptors in memory functions [55]. These findings indicate that ETB receptors play an important role in CNS disorders. ETB receptor deficiency at birth results in a decrease in neuronal progenitor cells and an increase in apoptosis in the postnatal cerebellum and dentate gyrus of rats [13, 14]. ETB receptor expression is enhanced in astrocytes following brain injury, while ET production is increased in the injured neurons [56, 57]. The stimulation of the glial ETB receptors by ET-1 results in the release of angiogenic and neurotrophic factors [54, 57].

1.7. Potential Clinical Implications of using ETB Receptor Agonist in Cerebral Ischemia

Several decades ago, it was recognized that ET and its receptors could be potential therapeutic targets to treat and/or prevent ischemic stroke. ET levels in the blood were elevated following ischemic stroke and subarachnoid hemorrhage, furthermore, ET immunoreactivity was increased in the ipsilateral compared with the contralateral hemisphere (119% after 24 h; 184% after 48 h and 459% after 72 h) in rats with cerebral ischemia [58]. ET has been reported to have pathophysiological role in neuronal injury due to ischemia [59]. ET-1 has a strong contractile effect on the cerebral arterial blood vessels [58, 60], producing major reduction in cerebral blood flow leading to infarction and neurological deficits [61]. An increase in ET-1 levels coincided with a decrease in regional cerebral blood flow in the ischemic areas following experimental stroke, these findings prompted investigation of ET receptor antagonists in the treatment of focal ischemic stroke [62]. Selectively blocking ETA receptors in closed head injury and ischemic stroke was found to significantly improve neurological outcome [63, 64]. The volume of infarction following focal cerebral ischemia in rat was reduced by non-selective ETA and ETB receptor antagonist TAK-044 and selective ETA antagonist, BQ123 [65, 66]. ETA specific and non-specific ETA and ETB receptor antagonists showed promising results in experimental stroke models [63, 65, 67] but were not successful in clinical trials [68, 69]. A majority of research has focused on selectively antagonizing the ETA receptors to prevent vasoconstriction following stroke.

We have demonstrated that ETB receptors in the brain are over expressed at the time of birth and their expression decreases with maturity of the brain [37, 40]. It has been shown that damaged brain exhibits a re-emergence of childhood organizational patterns, reminiscent of an ontogenetic state [70] and is primed for recovery. However, endogenous remodeling of the CNS is not sufficient to restore neurological function. Evidence that a deficiency in ETB receptors leads to a poorer outcome following cerebral ischemia [71] and deficiency or blockade of ETB receptors leads to exacerbation of damage to the CNS following ischemia [72] suggesting that a role of ETB receptors in pathophysiological process of ischemic stroke should be investigated (Fig. 2).

Fig. (2).

Fig. (2)

Cerebral ischemia produces a wide variety of changes in the CNS. They can broadly be classified as injury and repair mechanisms. It is our hypothesis that ETB receptor agonist, IRL-1620, may be acting a neuroprotective and may also participate in the repair mechanism following cerebral ischemia. It has been demonstrated that IRL-1620 is both neuroprotective and participates in the repair mechanism in animal model of cerebral ischemia.

We have shown that selectively activating ETB receptors, with IRL-1620, in a focal stroke model has been shown to be effective in reducing the infarct volume to 24.47±4.37 mm3 versus 153.23±32.18mm3 in vehicle-treated rats 24 hours after infarction. In another study, rats received three injections of either vehicle or IRL-1620 (each dose of 5 µg/kg) intravenously at 2, 4, and 6 hours after permanent occlusion, rats were observed for 7 days and it was found that treatment with IRL-1620 significantly reduced infarct volume (54.06 ± 14.12 mm3 vs. 177.06 ± 13.21 mm3) and improved all the parameters depicting neurological and motor functions when compared to the vehicle-treated group [73-75]. An increase in plasma ET-1 levels and tissue ET immunoreactivity, combined with evidence that a deficiency in ETB receptors leads to a poorer outcome following cerebral ischemia [58, 71] indicates that there is involvement of ETB receptors in brain ischemia. Deficiency or blockade of ETB receptors exacerbates ischemic brain damage, possibly due to a shift in ET vasomotor balance [71, 72]. It was found that protection and recovery from cerebral ischemia was at least partially due to an increase in angiogenesis and neurogenesis within 7 days following treatment with IRL-1620. The count of VEGF-positive vessels/30 µm brain slice in the IRL-1620 group were significantly higher (11.33±2.13) versus vehicle group (4.19±0.79) [75]. An increase in the vascular and nerve growth factors in the ischemic brain hemisphere of IRL-1620-treated animals coincided with an increase in the expression of ETB receptors. Moreover, functional ETB receptors have been shown to protect against apoptosis and enhance the proliferation of neuronal progenitors in the dentate gyrus, olfactory epithelium and cortical neurons [72, 76-78].

ETB receptor stimulation, via IRL-1620, significantly reduced neurological deficit, improved motor functions and oxidative stress markers and decreased infarct volume following ischemia in rats [73, 74]. Additionally, IRL-1620 provided marked neuroprotection at both 24 hours [73] and 7 days [74] following occlusion of the middle cerebral artery and reduced infarct volume by 83.66% in the acute study and 69.49% in the chronic study. IRL-1620 treatment preserved neuronal numbers in the cerebral cortex, striatum and SVZ and also increased ETB receptor expression in the ischemic hemisphere of the rat brain. IRL-1620 treatment also enhanced the number of blood vessels that labeled positive with VEGF when compared to the vehicle treatment [75]. Thus, IRL-1620, when administered intravenously, was found to be highly effective in preventing damage following stroke and helped in the neurovascular remodeling of the ischemic brain by angiogenesis and neurogenesis [75].

2. CONCLUSION

About 795,000 people experience a new or recurrent stroke each year and 610,000 of these are first attacks, and balance 185,000 are recurrent attacks. Eighty seven percent of all strokes are ischemic and balance thirteen percent are hemorrhagic [79]. The two major approaches that can be used for the treatment of cerebral ischemia are neuroprotection, which requires an acute intervention, and neurorestoration, which can be instituted during the stroke recovery phase [80-82] (Fig. 2). Several trials have been conducted or are in progress using pharmacological agents such as amphetamine, methylphenidate, levodopa, sildenafil, serotonin uptake inhibitors, erythropoietin, statins, and granulocyte colony stimulating factor but none involves stimulation of ETB receptors. It will be of great interest to determine whether stimulation of ETB receptors produces neuroprotection or neurorestoration (reparative and regenerative) or both through the involvement of mitochondria. It is also worthwhile exploring the neuroprotective and neurorestorative role of ETB receptors in the brain and may form the basis for the design of novel and effective strategies for the treatment of ischemia-induced brain damage.

ACKNOWLEDGEMENTS

I would like to give my sincere appreciation to Dr. Mary Leonard and Dr. Seema Briyal for conducting most of cerebral ischemia experiments in our laboratory and to Ms. Shruti Gulati for assisting in writing this article.

CONFLICT OF INTEREST

Pending patent application related to neurogenesis.

REFERENCES

  • 1.Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–415. doi: 10.1038/332411a0. [http://dx.doi.
org/10.1038/332411a0]. [PMID: 2451132]. [DOI] [PubMed] [Google Scholar]
  • 2.Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA. 1989;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [http://dx.doi.org/10.1073/pnas.86.8.2863]. [PMID: 2649896]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348(6303):730–732. doi: 10.1038/348730a0. [http://dx.doi.org/10.1038/ 348730a0]. [PMID: 2175396]. [DOI] [PubMed] [Google Scholar]
  • 4.Sakurai T., Yanagisawa M., Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. 1992;13(3):103–108. doi: 10.1016/0165-6147(92)90038-8. [PMID: 1315462]. [DOI] [PubMed] [Google Scholar]
  • 5.Goto K., Kasuya Y., Matsuki N., Takuwa Y., Kurihara H., Ishikawa T., Kimura S., Yanagisawa M., Masaki T. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc. Natl. Acad. Sci. USA. 1989;86(10):3915–3918. doi: 10.1073/pnas.86.10.3915. [http://dx.doi.org/10.1073/pnas.86.10. 3915]. [PMID: 2542956]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Tsukahara H., Ende H., Magazine H.I., Bahou W.F., Goligorsky M.S. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J. Biol. Chem. 1994;269(34):21778–21785. [PMID: 7520443]. [PubMed] [Google Scholar]
  • 7.Warner T.D., Allcock G.H., Corder R., Vane J.R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br. J. Pharmacol. 1993;110(2):777–782. doi: 10.1111/j.1476-5381.1993.tb13879.x. [http://dx.doi.org/10.1111/j.1476-5381.1993.tb13879.x]. [PMID: 8242251]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.MacCumber M.W., Ross C.A., Snyder S.H. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc. Natl. Acad. Sci. USA. 1990;87(6):2359–2363. doi: 10.1073/pnas.87.6.2359. [http://dx.doi.org/10. 1073/pnas.87.6.2359]. [PMID: 2156267]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gulati A., Srimal R.C. Endothelin mechanisms in the central nervous system - A target for drug development. Drug Dev. Res. 1992;26(4):361–387. [http://dx.doi.org/10.1002/ddr.430260402]. [Google Scholar]
  • 10.Gulati A., Srimal R.C. Endothelin antagonizes the hypotension and potentiates the hypertension induced by clonidine. Eur. J. Pharmacol. 1993;230(3):293–300. doi: 10.1016/0014-2999(93)90564-x. [http://dx.doi.org/10.1016/ 0014-2999(93)90564-X]. [PMID: 8440307]. [DOI] [PubMed] [Google Scholar]
  • 11.Kumar A., Gulati A., Shahani B.T. Central cardiovascular effects of endothelin-1 (ET-1) could be attenuated by propranalol in rats. Circulation. 1995;92(8):1054–1054. [Google Scholar]
  • 12.Kumar A., Shahani B.T., Gulati A. Modification of systemic and regional circulatory effects of intracerebroventricular administration of endothelin-1 by propranolol in anesthetized rats. Gen. Pharmacol. 1996;27(6):1025–1033. doi: 10.1016/0306-3623(95)02134-5. [http://dx.doi.org/10.1016/ 0306-3623(95)02134-5]. [PMID: 8909986]. [DOI] [PubMed] [Google Scholar]
  • 13.Ehrenreich H., Nau T.R., Dembowski C., Hasselblatt M., Barth M., Hahn A., Schilling L., Sirén A-L., Brück W. Endothelin b receptor deficiency is associated with an increased rate of neuronal apoptosis in the dentate gyrus. Neuroscience. 2000;95(4):993–1001. doi: 10.1016/s0306-4522(99)00507-2. [http://dx.doi.org/10.1016/S0306-4522(99)00507-2]. [PMID: 10682706]. [DOI] [PubMed] [Google Scholar]
  • 14.Vidovic M., Chen M.M., Lu Q.Y., Kalloniatis K.F., Martin B.M., Tan A.H., Lynch C., Croaker G.D., Cass D.T., Song Z.M. Deficiency in endothelin receptor B reduces proliferation of neuronal progenitors and increases apoptosis in postnatal rat cerebellum. Cell. Mol. Neurobiol. 2008;28(8):1129–1138. doi: 10.1007/s10571-008-9292-z. [http://dx.doi.org/10.1007/s10571-008-9292-z]. [PMID: 18683040]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Druckenbrod N.R., Powers P.A., Bartley C.R., Walker J.W., Epstein M.L. Targeting of endothelin receptor-B to the neural crest. Genesis. 2008;46(8):396–400. doi: 10.1002/dvg.20415. [http://dx.doi.org/10.1002/ dvg.20415]. [PMID: 18693272]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Riechers C.C., Knabe W., Sirén A.L., Gariepy C.E., Yanagisawa M., Ehrenreich H. Endothelin B receptor deficient transgenic rescue rats: a rescue phenomenon in the brain. Neuroscience. 2004;124(4):719–723. doi: 10.1016/j.neuroscience.2003.10.023. [http://dx.doi.org/10.1016/ j.neuroscience.2003.10.023]. [PMID: 15026112]. [DOI] [PubMed] [Google Scholar]
  • 17.Castañeda M.M., Cubilla M.A., López-Vicchi M.M., Suburo A.M. Endothelinergic cells in the subependymal region of mice. Brain Res. 2010;1321:20–30. doi: 10.1016/j.brainres.2010.01.056. [http://dx.doi.org/10.1016/j. brainres.2010.01.056]. [PMID: 20116370]. [DOI] [PubMed] [Google Scholar]
  • 18.Koyama Y., Baba A., Matsuda T. Endothelins stimulate the expression of neurotrophin-3 in rat brain and rat cultured astrocytes. Neuroscience. 2005;136(2):425–433. doi: 10.1016/j.neuroscience.2005.08.004. [http://dx.doi.org/10.1016/ j.neuroscience.2005.08.004]. [PMID: 16181740]. [DOI] [PubMed] [Google Scholar]
  • 19.Koyama Y., Tsujikawa K., Matsuda T., Baba A. Intra- cerebroventricular administration of an endothelin ETB receptor agonist increases expressions of GDNF and BDNF in rat brain. Eur. J. Neurosci. 2003;18(4):887–894. doi: 10.1046/j.1460-9568.2003.02797.x. [http://dx.doi.org/10.1046/ j.1460-9568.2003.02797.x]. [PMID: 12925014]. [DOI] [PubMed] [Google Scholar]
  • 20.De Giusti V.C., Correa M.V., Villa-Abrille M.C., Beltrano C., Yeves A.M., de Cingolani G.E., Cingolani H.E., Aiello E.A. The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci. 2008;83(7-8):264–271. doi: 10.1016/j.lfs.2008.06.008. [http://dx.doi.org/10.1016/j.lfs.2008.06.008]. [PMID: 18625248]. [DOI] [PubMed] [Google Scholar]
  • 21.Yuki K., Miyauchi T., Kakinuma Y., Murakoshi N., Suzuki T., Hayashi J., Goto K., Yamaguchi I. Mitochondrial dysfunction increases expression of endothelin-1 and induces apoptosis through caspase-3 activation in rat cardiomyocytes in vitro. J. Cardiovasc. Pharmacol. 2000;36(5) Suppl. 1:S205–S208. doi: 10.1097/00005344-200036051-00062. [http://dx.doi.org/
10.1097/00005344-200036051-00062]. [PMID: 11078378]. [DOI] [PubMed] [Google Scholar]
  • 22.Marín-García J., Goldenthal M.J., Moe G.W. Selective endothelin receptor blockade reverses mitochondrial dysfunction in canine heart failure. J. Card. Fail. 2002;8(5):326–332. doi: 10.1054/jcaf.2002.127770. [http://dx. doi.org/10.1054/jcaf.2002.127770]. [PMID: 12411984]. [DOI] [PubMed] [Google Scholar]
  • 23.Ouyang J.S., Li Y.P., Li C.Y., Cai C., Chen C.S., Chen S.X., Chen Y.F., Yang L., Xie Y.P. Mitochondrial ROS-K+ channel signaling pathway regulated secretion of human pulmonary artery endothelial cells. Free Radic. Res. 2012;46(12):1437–1445. doi: 10.3109/10715762.2012.724532. [http://dx.doi.org/10.3109/10715762.2012.724532]. [PMID: 22928487]. [DOI] [PubMed] [Google Scholar]
  • 24.Bagnato A., Natali P.G. Endothelin receptors as novel targets in tumor therapy. J. Transl. Med. 2004;2(1):16. doi: 10.1186/1479-5876-2-16. [http://dx.doi.org/
10.1186/1479-5876-2-16]. [PMID: 15165288]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Paolillo M., Russo M.A., Curti D., Lanni C., Schinelli S. Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells. Pharmacol. Res. 2010;61(4):306–315. doi: 10.1016/j.phrs.2009.11.003. [http://dx.doi.org/10.1016/j.phrs.2009.11.003]. [PMID: 19931393]. [DOI] [PubMed] [Google Scholar]
  • 26.Alvarez-Buylla A., Lim D.A. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004;41(5):683–686. doi: 10.1016/s0896-6273(04)00111-4. [http://dx.doi.org/10.1016/S0896-6273(04)00111-4]. [PMID: 15003168]. [DOI] [PubMed] [Google Scholar]
  • 27.Barnabé-Heider F., Göritz C., Sabelström H., Takebayashi H., Pfrieger F.W., Meletis K., Frisén J. Origin of new glial cells in intact and injured adult spinal cord. Cell Stem Cell. 2010;7(4):470–482. doi: 10.1016/j.stem.2010.07.014. [http://dx.doi.org/10.1016/j.stem.2010.07.014]. [PMID: 20887953]. [DOI] [PubMed] [Google Scholar]
  • 28.Anderson M.F., Aberg M.A., Nilsson M., Eriksson P.S. Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res. Dev. Brain Res. 2002;134(1-2):115–122. doi: 10.1016/s0165-3806(02)00277-8. [http://
dx.doi.org/10.1016/S0165-3806(02)00277-8]. [PMID: 11947942]. [DOI] [PubMed] [Google Scholar]
  • 29.Thau-Zuchman O., Shohami E., Alexandrovich A.G., Leker R.R. Vascular endothelial growth factor increases neurogenesis after traumatic brain injury. J. Cereb. Blood Flow Metab. 2010;30(5):1008–1016. doi: 10.1038/jcbfm.2009.271. [http://dx.doi.org/10.1038/jcbfm.2009.271]. [PMID: 20068579]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000;20(24):9104–9110. doi: 10.1523/JNEUROSCI.20-24-09104.2000. [PMID: 11124987]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Pakkenberg B., Gundersen H.J. Neocortical neuron number in humans: effect of sex and age. J. Comp. Neurol. 1997;384(2):312–320. [http://dx.doi.org/10.1002/(SICI)1096-9861(19970728) 384:2<312:AID-CNE10>3.0.CO;2-K]. [PMID: 9215725]. [PubMed] [Google Scholar]
  • 32.Kriegstein A., Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. Annu. Rev. Neurosci. 2009;32:149–184. doi: 10.1146/annurev.neuro.051508.135600. [http://dx.doi.org/10.1146/annurev.neuro.051508.135600]. [PMID: 19555289]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Eriksson P.S., Perfilieva E., Björk-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., Gage F.H. Neurogenesis in the adult human hippocampus. Nat. Med. 1998;4(11):1313–1317. doi: 10.1038/3305. [http://dx.doi.org/10.1038/3305]. [PMID: 9809557]. [DOI] [PubMed] [Google Scholar]
  • 34.Kempermann G., Kuhn H.G., Gage F.H. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997;386(6624):493–495. doi: 10.1038/386493a0. [http://dx.doi.org/10.1038/386493a0]. [PMID: 9087407]. [DOI] [PubMed] [Google Scholar]
  • 35.Wodarz A., Huttner W.B. Asymmetric cell division during neurogenesis in Drosophila and vertebrates. Mech. Dev. 2003;120(11):1297–1309. doi: 10.1016/j.mod.2003.06.003. [http://dx.doi.org/10.1016/j.mod.2003.06.003]. [PMID: 14623439]. [DOI] [PubMed] [Google Scholar]
  • 36.Clancy B., Darlington R.B., Finlay B.L. Translating developmental time across mammalian species. Neuroscience. 2001;105(1):7–17. doi: 10.1016/s0306-4522(01)00171-3. [http://dx.doi.org/10.1016/S0306-4522(01) 00171-3]. [PMID: 11483296]. [DOI] [PubMed] [Google Scholar]
  • 37.Briyal S., Lavhale M.S., Gulati A. Repeated administration of centhaquin to pregnant rats did not affect postnatal development and expression of endothelin receptors in the brain, heart or kidney of pups. Arzneimittelforschung. 2012;62(12):670–676. doi: 10.1055/s-0032-1329985. [http://dx. doi.org/10.1055/s-0032-1329985]. [PMID: 23154885]. [DOI] [PubMed] [Google Scholar]
  • 38.Briyal S., Shepard C., Gulati A. Endothelin receptor type B agonist, IRL-1620, prevents beta amyloid (Aβ) induced oxidative stress and cognitive impairment in normal and diabetic rats. Pharmacol. Biochem. Behav. 2014;120:65–72. doi: 10.1016/j.pbb.2014.02.008. [http://dx.doi.org/
10.1016/j.pbb.2014.02.008]. [PMID: 24561065]. [DOI] [PubMed] [Google Scholar]
  • 39.Leonard M.G., Prazad P., Puppala B., Gulati A. Selective Endothelin-B receptor stimulation increases vascular endothelial growth factor in the rat brain during postnatal development. Drug Res (Stuttg) 2015 doi: 10.1055/s-0034-1398688. [DOI] [PubMed] [Google Scholar]
  • 40.Puppala B., Awan I., Briyal S., Mbachu O., Leonard M., Gulati A. Ontogeny of endothelin receptors in the brain, heart, and kidneys of neonatal rats. Brain Dev. 2015;37(2):206–215. doi: 10.1016/j.braindev.2014.04.008. [http://
dx.doi.org/10.1016/j.braindev.2014.04.008]. [PMID: 24815227]. [DOI] [PubMed] [Google Scholar]
  • 41.Yuan Y., Zhang X., Zheng Y., Chen Z. Regulation of mitophagy in ischemic brain injury. Neurosci. Bull. 2015;31(4):395–406. doi: 10.1007/s12264-015-1544-6. [http://dx.doi.org/10.1007/s12264-015-1544-6]. [PMID: 26219224]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Banerjee K., Munshi S., Frank D.E., Gibson G.E. Abnormal Glucose Metabolism in Alzheimer’s Disease: Relation to Autophagy/Mitophagy and Therapeutic Approaches. Neurochem. Res. 2015;40(12):2557–2569. doi: 10.1007/s11064-015-1631-0. [http://dx.doi.org/10.1007/s11064-015-1631-0]. [PMID: 26077923]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Meijer A.J., Codogno P. Autophagy: regulation and role in disease. Crit. Rev. Clin. Lab. Sci. 2009;46(4):210–240. doi: 10.1080/10408360903044068. [http://dx. doi.org/10.1080/10408360903044068]. [PMID: 19552522]. [DOI] [PubMed] [Google Scholar]
  • 44.Santos R.X., Correia S.C., Wang X., Perry G., Smith M.A., Moreira P.I., Zhu X. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease. J. Alzheimers Dis. 2010;20(Suppl. 2):S401–S412. doi: 10.3233/JAD-2010-100666. [PMID: 20463393]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Vives-Bauza C., Przedborski S. Mitophagy: the latest problem for Parkinson’s disease. Trends Mol. Med. 2011;17(3):158–165. doi: 10.1016/j.molmed.2010.11.002. [http://
dx.doi.org/10.1016/j.molmed.2010.11.002]. [PMID: 21146459]. [DOI] [PubMed] [Google Scholar]
  • 46.Zhang X., Yan H., Yuan Y., Gao J., Shen Z., Cheng Y., Shen Y., Wang R.R., Wang X., Hu W.W., Wang G., Chen Z. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. Autophagy. 2013;9(9):1321–1333. doi: 10.4161/auto.25132. [http://dx.doi.org/10.4161/auto.25132]. [PMID: 23800795]. [DOI] [PubMed] [Google Scholar]
  • 47.Xavier J.M., Rodrigues C.M., Solá S. Mitochondria: Major Regulators of Neural Development. Neuroscientist. 2015:1073858415585472. doi: 10.1177/1073858415585472. [PMID: 25948649]. [DOI] [PubMed] [Google Scholar]
  • 48.Cheng A., Hou Y., Mattson M.P. Mitochondria and neuro- plasticity. ASN Neuro. 2010;2(5):e00045. doi: 10.1042/AN20100019. [http://dx.doi.org/10. 1042/AN20100019]. [PMID: 20957078]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Mattson M.P., Liu D. Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem. Biophys. Res. Commun. 2003;304(3):539–549. doi: 10.1016/s0006-291x(03)00627-2. [http://dx.doi.org/10.1016/S0006-291X(03)00627-2]. [PMID: 12729589]. [DOI] [PubMed] [Google Scholar]
  • 50.Kann O., Kovács R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007;292(2):C641–C657. doi: 10.1152/ajpcell.00222.2006. [http://dx.doi.org/
10.1152/ajpcell.00222.2006]. [PMID: 17092996]. [DOI] [PubMed] [Google Scholar]
  • 51.Acker T., Acker H. Cellular oxygen sensing need in CNS function: physiological and pathological implications. J. Exp. Biol. 2004;207(Pt 18):3171–3188. doi: 10.1242/jeb.01075. [http://dx.doi.org/10.1242/jeb.01075]. [PMID: 15299039]. [DOI] [PubMed] [Google Scholar]
  • 52.Schänzer A., Wachs F.P., Wilhelm D., Acker T., Cooper-Kuhn C., Beck H., Winkler J., Aigner L., Plate K.H., Kuhn H.G. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol. 2004;14(3):237–248. doi: 10.1111/j.1750-3639.2004.tb00060.x. [http://dx.doi.org/10.1111/j.1750-3639.2004.tb00060.x]. [PMID: 15446578]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Sisalli M.J., Annunziato L., Scorziello A. Novel Cellular Mechanisms for Neuroprotection in Ischemic Preconditioning: A View from Inside Organelles. Front. Neurol. 2015;6:115. doi: 10.3389/fneur.2015.00115. [http://dx.doi.org/10.3389/fneur.2015.00115]. [PMID: 26074868]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Koyama Y., Michinaga S. Regulations of astrocytic functions by endothelins: roles in the pathophysiological responses of damaged brains. J. Pharmacol. Sci. 2012;118(4):401–407. doi: 10.1254/jphs.11r13cp. [http://dx.doi.
org/10.1254/jphs.11R13CP]. [PMID: 22447302]. [DOI] [PubMed] [Google Scholar]
  • 55.Briyal S., Philip T., Gulati A. Endothelin-A receptor antagonists prevent amyloid-β-induced increase in ETA receptor expression, oxidative stress, and cognitive impairment. J. Alzheimers Dis. 2011;23(3):491–503. doi: 10.3233/JAD-2010-101245. [PMID: 21116051]. [DOI] [PubMed] [Google Scholar]
  • 56.Nakagomi S., Kiryu-Seo S., Kiyama H. Endothelin-converting enzymes and endothelin receptor B messenger RNAs are expressed in different neural cell species and these messenger RNAs are coordinately induced in neurons and astrocytes respectively following nerve injury. Neuroscience. 2000;101(2):441–449. doi: 10.1016/s0306-4522(00)00345-6. [http://dx.doi.org/10.1016/S0306-4522(00)00345-6]. [PMID: 11074166]. [DOI] [PubMed] [Google Scholar]
  • 57.Rogers S.D., Demaster E., Catton M., Ghilardi J.R., Levin L.A., Maggio J.E., Mantyh P.W. Expression of endothelin-B receptors by glia in vivo is increased after CNS injury in rats, rabbits, and humans. Exp. Neurol. 1997;145(1):180–195. doi: 10.1006/exnr.1997.6468. [http://dx.doi.org/10. 1006/exnr.1997.6468]. [PMID: 9184120]. [DOI] [PubMed] [Google Scholar]
  • 58.Viossat I., Duverger D., Chapelat M., Pirotzky E., Chabrier P.E., Braquet P. Elevated tissue endothelin content during focal cerebral ischemia in the rat. J. Cardiovasc. Pharmacol. 1993;22(Suppl. 8):S306–S309. doi: 10.1097/00005344-199322008-00080. [http://dx.doi.org/10.1097/00005344-199322008-00080]. [PMID: 7509972]. [DOI] [PubMed] [Google Scholar]
  • 59.Willette R.N., Ohlstein E.H., Pullen M., Sauermelch C.F., Cohen A., Nambi P. Transient forebrain ischemia alters acutely endothelin receptor density and immunoreactivity in gerbil brain. Life Sci. 1993;52(1):35–40. doi: 10.1016/0024-3205(93)90286-c. [http://dx.doi.org/10.1016/0024-3205(93)90286-C]. [PMID: 8417278]. [DOI] [PubMed] [Google Scholar]
  • 60.Lee M.E., de la Monte S.M., Ng S.C., Bloch K.D., Quertermous T. Expression of the potent vasoconstrictor endothelin in the human central nervous system. J. Clin. Invest. 1990;86(1):141–147. doi: 10.1172/JCI114677. [http://dx.doi.org/10.1172/JCI114677]. [PMID: 2195059]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Robinson M.J., Macrae I.M., Todd M., Reid J.L., McCulloch J. Reduction of local cerebral blood flow to pathological levels by endothelin-1 applied to the middle cerebral artery in the rat. Neurosci. Lett. 1990;118(2):269–272. doi: 10.1016/0304-3940(90)90644-o. [http://dx.doi.org/10.1016/ 0304-3940(90)90644-O]. [PMID: 2274283]. [DOI] [PubMed] [Google Scholar]
  • 62.Patel T.R., Galbraith S.L., McAuley M.A., Doherty A.M., Graham D.I., McCulloch J. Therapeutic potential of endothelin receptor antagonists in experimental stroke. J. Cardiovasc. Pharmacol. 1995;26(Suppl. 3):S412–S415. [http://dx.doi.org/10. 1097/00005344-199506263-00121]. [PMID: 8587430]. [PubMed] [Google Scholar]
  • 63.Barone F.C., Ohlstein E.H., Hunter A.J., Campbell C.A., Hadingham S.H., Parsons A.A., Yang Y., Shohami E. Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat. J. Cardiovasc. Pharmacol. 2000;36(5) Suppl. 1:S357–S361. doi: 10.1097/00005344-200036051-00104. [http://dx.doi.org/10.1097/ 00005344-200036051-00104]. [PMID: 11078420]. [DOI] [PubMed] [Google Scholar]
  • 64.Legos J.J., Lenhard S.C., Haimbach R.E., Schaeffer T.R., Bentley R.G., McVey M.J., Chandra S., Irving E.A., Andrew A. Parsons; Barone, F.C. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp. Neurol. 2008;212(1):53–62. doi: 10.1016/j.expneurol.2008.03.011. [http://dx.doi.org/10.1016/j. expneurol.2008.03.011]. [PMID: 18462720]. [DOI] [PubMed] [Google Scholar]
  • 65.Briyal S., Gulati A. Endothelin-A receptor antagonist BQ123 potentiates acetaminophen induced hypothermia and reduces infarction following focal cerebral ischemia in rats. Eur. J. Pharmacol. 2010;644(1-3):73–79. doi: 10.1016/j.ejphar.2010.06.071. [http://dx.doi.org/10.1016/ j.ejphar.2010.06.071]. [PMID: 20638381]. [DOI] [PubMed] [Google Scholar]
  • 66.Briyal S., Gulati A., Gupta Y.K. Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. Methods Find. Exp. Clin. Pharmacol. 2007;29(4):257–263. doi: 10.1358/mf.2007.29.4.1106409. [http://dx.doi.org/10.1358/mf.2007.29.4.1106409]. [PMID: 17609737]. [DOI] [PubMed] [Google Scholar]
  • 67.Gupta Y.K., Briyal S., Sharma U., Jagannathan N.R., Gulati A. Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats. Life Sci. 2005;77(1):15–27. doi: 10.1016/j.lfs.2004.11.025. [http://dx.doi.org/10.1016/j.lfs.2004. 11.025]. [PMID: 15848215]. [DOI] [PubMed] [Google Scholar]
  • 68.Kohan D.E., Cleland J.G., Rubin L.J., Theodorescu D., Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012;91(13-14):528–539. doi: 10.1016/j.lfs.2012.07.034. [http://dx.doi.org/10.1016/j.lfs.2012.07.034]. [PMID: 22967485]. [DOI] [PubMed] [Google Scholar]
  • 69.Shah R. Endothelins in health and disease. Eur. J. Intern. Med. 2007;18(4):272–282. doi: 10.1016/j.ejim.2007.04.002. [http://dx.doi.org/10.1016/j.ejim.2007.04. 002]. [PMID: 17574100]. [DOI] [PubMed] [Google Scholar]
  • 70.Cramer S.C., Chopp M. Recovery recapitulates ontogeny. Trends Neurosci. 2000;23(6):265–271. doi: 10.1016/s0166-2236(00)01562-9. [http://dx.doi.org/10.1016/S0166-2236(00)01562-9]. [PMID: 10838596]. [DOI] [PubMed] [Google Scholar]
  • 71.Chuquet J., Benchenane K., Toutain J., MacKenzie E.T., Roussel S., Touzani O. Selective blockade of endothelin-B receptors exacerbates ischemic brain damage in the rat. Stroke. 2002;33(12):3019–3025. doi: 10.1161/01.str.0000039401.48915.9f. [http://dx.doi.org/10.1161/01.STR. 0000039401.48915.9F]. [PMID: 12468806]. [DOI] [PubMed] [Google Scholar]
  • 72.Ehrenreich H., Oldenburg J., Hasselblatt M., Herms J., Dembowski C., Löffler B.M., Brück W., Kamrowski-Kruck H., Gall S., Sirén A.L., Schilling L. Endothelin B receptor-deficient rats as a subtraction model to study the cerebral endothelin system. Neuroscience. 1999;91(3):1067–1075. doi: 10.1016/s0306-4522(98)00663-0. [http://dx.doi.org/10.1016/ S0306-4522(98)00663-0]. [PMID: 10391484]. [DOI] [PubMed] [Google Scholar]
  • 73.Leonard M.G., Briyal S., Gulati A. Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain Res. 2011;1420:48–58. doi: 10.1016/j.brainres.2011.08.075. [http://dx.doi.org/10.1016/j.brainres.2011. 08.075]. [PMID: 21959172]. [DOI] [PubMed] [Google Scholar]
  • 74.Leonard M.G., Briyal S., Gulati A. Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats. Brain Res. 2012;1464:14–23. doi: 10.1016/j.brainres.2012.05.005. [http://dx.doi.org/
10.1016/j.brainres.2012.05.005]. [PMID: 22580085]. [DOI] [PubMed] [Google Scholar]
  • 75.Leonard M.G., Gulati A. Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain Res. 2013;1528:28–41. doi: 10.1016/j.brainres.2013.07.002. [http://dx.doi.org/
10.1016/j.brainres.2013.07.002]. [PMID: 23850649]. [DOI] [PubMed] [Google Scholar]
  • 76.Laziz I., Larbi A., Grebert D., Sautel M., Congar P., Lacroix M.C., Salesse R., Meunier N. Endothelin as a neuroprotective factor in the olfactory epithelium. Neuroscience. 2011;172:20–29. doi: 10.1016/j.neuroscience.2010.10.063. [http://dx.doi.org/10.1016/j.neuroscience.2010.10.063]. [PMID: 21035524]. [DOI] [PubMed] [Google Scholar]
  • 77.Lee H.O., Levorse J.M., Shin M.K. The endothelin receptor-B is required for the migration of neural crest-derived melanocyte and enteric neuron precursors. Dev. Biol. 2003;259(1):162–175. doi: 10.1016/s0012-1606(03)00160-x. [http://dx.doi.org/10.1016/S0012-1606(03)00160-X]. [PMID: 12812796]. [DOI] [PubMed] [Google Scholar]
  • 78.Yagami T., Ueda K., Sakaeda T., Okamura N., Nakazato H., Kuroda T., Hata S., Sakaguchi G., Itoh N., Hashimoto Y., Fujimoto M. Effects of an endothelin B receptor agonist on secretory phospholipase A2-IIA-induced apoptosis in cortical neurons. Neuropharmacology. 2005;48(2):291–300. doi: 10.1016/j.neuropharm.2004.09.011. [http://dx. doi.org/10.1016/j.neuropharm.2004.09.011]. [PMID: 15695168]. [DOI] [PubMed] [Google Scholar]
  • 79.Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., Bravata D.M., Dai S., Ford E.S., Fox C.S., Franco S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., Howard V.J., Huffman M.D., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Magid D., Marcus G.M., Marelli A., Matchar D.B., McGuire D.K., Mohler E.R., Moy C.S., Mussolino M.E., Nichol G., Paynter N.P., Schreiner P.J., Sorlie P.D., Stein J., Turan T.N., Virani S.S., Wong N.D., Woo D., Turner M.B. Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143–152. doi: 10.1161/CIR.0b013e318282ab8f. [http://dx.doi.org/10.1161/CIR.0b013e318282ab8f]. [PMID: 23283859]. [DOI] [PubMed] [Google Scholar]
  • 80.Andres R.H., Horie N., Slikker W., Keren-Gill H., Zhan K., Sun G., Manley N.C., Pereira M.P., Sheikh L.A., McMillan E.L., Schaar B.T., Svendsen C.N., Bliss T.M., Steinberg G.K. Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain. 2011;134(Pt 6):1777–1789. doi: 10.1093/brain/awr094. [http://dx.doi.org/10.1093/brain/awr094]. [PMID: 21616972]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Bacigaluppi M., Pluchino S., Peruzzotti-Jametti L., Kilic E., Kilic U., Salani G., Brambilla E., West M.J., Comi G., Martino G., Hermann D.M. Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain. 2009;132(Pt 8):2239–2251. doi: 10.1093/brain/awp174. [http://dx.doi.org/10.1093/brain/awp174]. [PMID: 19617198]. [DOI] [PubMed] [Google Scholar]
  • 82.Liu Z., Li Y., Zhang X., Savant-Bhonsale S., Chopp M. Contralesional axonal remodeling of the corticospinal system in adult rats after stroke and bone marrow stromal cell treatment. Stroke. 2008;39(9):2571–2577. doi: 10.1161/STROKEAHA.107.511659. [http://dx.doi.org/10.1161/ STROKEAHA.107.511659]. [PMID: 18617661]. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current Neuropharmacology are provided here courtesy of Bentham Science Publishers

RESOURCES